Selected article for: "antiviral activity and viral glycoprotein sensitivity"

Author: William E. Diehl; Mehmet H. Guney; Pyae Phyo Kyawe; Judith M. White; Massimo Pizzato; Jeremy Luban
Title: Influence of different glycoproteins and of the virion core on SERINC5 antiviral activity
  • Document date: 2019_9_24
  • ID: 9dybtdi2_9
    Snippet: Using this system, we tested the sensitivity of a number of retroviral Envs as well as representative glycoproteins from the Arenavirus, Coronavirus, Filovirus, Rhabdovirus, Paramyxovirus, and Orthomyxovirus genera. Consistent with previous findings, we observed that glycoprotein is a major determinant of SERINC5 sensitivity. While many glycoproteins were universally insensitive to the antiviral effects of SERINC5, the glycoproteins from NL4.3, A.....
    Document: Using this system, we tested the sensitivity of a number of retroviral Envs as well as representative glycoproteins from the Arenavirus, Coronavirus, Filovirus, Rhabdovirus, Paramyxovirus, and Orthomyxovirus genera. Consistent with previous findings, we observed that glycoprotein is a major determinant of SERINC5 sensitivity. While many glycoproteins were universally insensitive to the antiviral effects of SERINC5, the glycoproteins from NL4.3, A-MLV, and influenza were inhibited by SERINC5 in all viral core pseudotypes tested. No correlation was observed between SERINC5 sensitivity and the route of viral entry mediated by the viral glycoprotein. Unexpectedly, we also observed that sensitivity to SERINC5 antiviral activity for M-PMV, RD114, and rabies virus (RABV) glycoproteins depended on the retroviral core onto which they were pseudotyped. Our findings reveal that an interplay between virion core and glycoprotein determines the sensitivity to SERINC5 antiviral activity.

    Search related documents:
    Co phrase search for related documents
    • antiviral activity and MLV glycoprotein: 1
    • antiviral activity and Orthomyxovirus genera: 1, 2
    • antiviral activity and retroviral core: 1, 2
    • antiviral activity and viral entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral activity and viral glycoprotein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral effect and major determinant: 1
    • antiviral effect and viral entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • antiviral effect and viral glycoprotein: 1, 2, 3, 4, 5, 6, 7
    • major determinant and previous finding: 1
    • major determinant and viral entry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • major determinant and viral glycoprotein: 1, 2, 3, 4, 5
    • major determinant and viral glycoprotein mediate: 1
    • MLV glycoprotein and viral entry: 1, 2
    • MLV glycoprotein and viral glycoprotein: 1, 2
    • Orthomyxovirus genera and retroviral core: 1, 2
    • Orthomyxovirus genera and viral entry: 1, 2
    • Orthomyxovirus genera and viral glycoprotein: 1, 2
    • previous finding and viral entry: 1
    • representative glycoprotein and viral glycoprotein: 1